Medicare to Offer GLP-1 Weight-Loss Drugs Through Temporary Program
Medicare is set to begin offering GLP-1 weight-loss drugs to adults aged 65 and older starting next month, priced at $50 per prescription. This initiative, implemented through a government demonstration program, is designed to be temporary. The Trump administration is using this program to circumvent an existing legal prohibition that prevents Medicare from directly covering obesity drugs. However, concerns have been raised regarding the potential difficulty of discontinuing the program once it has been established.
Adults aged 65 and older enrolled in Medicare will gain access to weight-loss drugs for the first time starting next month. This availability is facilitated by a government program offering GLP-1 drugs for $50, which is intended to be a temporary measure.
Medicare is currently legally prohibited from covering obesity drugs. To bypass this restriction, the Trump administration has introduced a demonstration program, making these medications accessible to eligible beneficiaries.
Initially, Medicare had aimed to encourage private Medicare insurers to voluntarily cover these drugs through a three-year program named BALANCE. This program was intended to follow a brief transitional period. However, private insurers declined to participate in the BALANCE initiative.
As a result of the insurers' decision, the federal government is now extending the transitional coverage program, known as Bridge, until the end of next year. Despite its temporary designation, there are indications that ending this program might prove challenging once it is in place.
According to STAT News, the program's structure and implementation suggest it may be difficult to cease its operations once established. (Source: STAT News)
